BioDerm (Mountaingate) Acquires Argentum Medical

Mountaingate Capital Acquires BioDerm

January 11, 2021

Medical Devices

Denver-based private equity firm Mountaingate Capital has acquired BioDerm, Inc., a Largo, Florida manufacturer of disposable medical devices and wound care supplies, in a transaction supported by subordinated debt and an equity co-investment from Five Points Capital and additional financing from Abacus Finance Group. Mountaingate said it will accelerate BioDerm's organic growth and pursue add-on acquisitions to expand product and service offerings while management and founder shareholders retain a continued ownership/board role.

Argentum Medical Acquires Anacapa Technologies' Antimicrobial Wound-Care Product Lines

December 29, 2021

Medical Devices

Argentum Medical, a Shore Capital‑backed medical device company and maker of Silverlon dressings, has acquired Anacapa Technologies' antimicrobial wound cleansers, gels and irrigation product lines, including the Anasept and Silver‑Sept brands. The deal, completed on December 29, 2021, expands Argentum's wound‑care portfolio and integrates Anacapa's topical antimicrobial solutions into Argentum's existing product lineup for surgical, burn and chronic wound care.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

Nextmune Acquires VetBiotek

December 22, 2023

Veterinary

Nextmune, a global specialty animal-health company, acquired VetBiotek, a developer of veterinary dermatology topical formulations including MicroSilver BG and Ceramide III products. The acquisition expands Nextmune’s dermatology portfolio and aims to improve production, packaging, distribution and access of VetBiotek’s products to veterinary clinics and distributors.

DermBiont Acquires SeylanMED to Expand Dermatology Pipeline

October 21, 2020

Biotechnology

DermBiont, a Boston-based clinical-stage precision dermatology company, has acquired SeylanMED, adding a targeted topical AKT inhibitor gel candidate for seborrheic keratosis to its pipeline. The acquisition expands DermBiont's therapeutic modalities and accelerates its objective to develop targeted topical treatments and live bacterial therapeutics for skin diseases.

Arcutis Biotherapeutics Acquires Ducentis BioTherapeutics Ltd.

September 7, 2022

Biotechnology

Arcutis Biotherapeutics (Nasdaq: ARQT) has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical biotechnology company developing the CD200R agonist DS-234 for atopic dermatitis. The deal includes approximately $16 million in cash and roughly $14 million in Arcutis stock up front, plus contingent development-and-commercial milestones, and is intended to accelerate Arcutis' biologics pipeline and strengthen its dermatology capabilities.